Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Florence Cymbalista: iwCLL 2019, key points

Florence Cymbalista • 22 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Venetoclax

Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, discusses what the key points of discussion she expects to hear from the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK. Dr Cymbalista touches on combination therapies, novel agents and measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) treatment.

More from Florence Cymbalista

2:30
Towards strategies to optimize outcomes in CLL
Florence Cymbalista • 7 Oct 2022
2:07
Moving towards time-limited treatment in frontline CLL
Florence Cymbalista • 7 Oct 2022
2:27
The importance of TP53 & IGHV testing before treatment initiation in CLL
Florence Cymbalista • 7 Oct 2022
1:33
Challenges in interpreting the results of genomic tests in CLL
Florence Cymbalista • 7 Oct 2022

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals